America’s biopharmaceutical research companies are investigating or developing 93 medicines to help the more than five million patients in the United States who are living with Alzheimer’s. The medicines in development – all in either clinical trials or under review by the Food and Drug Administration – include 81 for Alzheimer’s, 11 for cognition disorders and 2 for dementias, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).
Alzheimer’s is one of the most complex diseases researchers have ever studied. There are many reasons Alzheimer’s research is so challenging. To start, the brain is the most complex and inaccessible organ in the body and the disease is correspondingly complicated. However, as our understanding of the disease grows so does our ability to find new potential treatment approaches and, ultimately, effective new medicines.
“Alzheimer’s disease prevents those affected from fighting for themselves, so it’s up to all of us to fight on their behalf,” said PhRMA President and CEO John J. Castellani. “Confronting this devastating disease of the brain will require continued collaboration in the scientific, medical and patient care communities and a commitment by policymakers to support and reward medical innovation.”
Resources
Release: From Setbacks to Stepping Stones: Alzheimer’s Disease
Report (2013): Medicines in Development for Alzheimer’s Diesease (PDF)
Backgrounder: Selected Medicines in Development for Alzheimer’s Disease
Alzheimer’s Disease Clinical Trials
SHAREEMAILPRINT
Sign-up for Updates
Subscribe to RSS
Related Content
Backgrounder: Selected Medicines in Development for Alzheimer’s
Read More About Medicines in Development for Alzheimer’s Disease
From Setbacks to Stepping Stones
Innovation is a Collaborative Mission
Rx Minute: Statins Value to Society & Risk Factors Linked to Alzheimer’s
Rx Minute: Alzheimer’s Burden Will Balloon if New Treatments Are Not Found
1 of 3next ›
More On PhRMA — powered by PhRMApedia
RESOURCES
Alzheimer's disease and dementia by Raymond W. Holman Jr. 
One Comment
America’s biopharmaceutical research companies are investigating or developing 93 medicines to help the more than five million patients in the United States who are living with Alzheimer’s. The medicines in development – all in either clinical trials or under review by the Food and Drug Administration – include 81 for Alzheimer’s, 11 for cognition disorders and 2 for dementias, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).
Alzheimer’s is one of the most complex diseases researchers have ever studied. There are many reasons Alzheimer’s research is so challenging. To start, the brain is the most complex and inaccessible organ in the body and the disease is correspondingly complicated. However, as our understanding of the disease grows so does our ability to find new potential treatment approaches and, ultimately, effective new medicines.
“Alzheimer’s disease prevents those affected from fighting for themselves, so it’s up to all of us to fight on their behalf,” said PhRMA President and CEO John J. Castellani. “Confronting this devastating disease of the brain will require continued collaboration in the scientific, medical and patient care communities and a commitment by policymakers to support and reward medical innovation.”
Resources
Release: From Setbacks to Stepping Stones: Alzheimer’s Disease
Report (2013): Medicines in Development for Alzheimer’s Diesease (PDF)
Backgrounder: Selected Medicines in Development for Alzheimer’s Disease
Alzheimer’s Disease Clinical Trials
SHAREEMAILPRINT
Sign-up for Updates
Subscribe to RSS
Related Content
Backgrounder: Selected Medicines in Development for Alzheimer’s
Read More About Medicines in Development for Alzheimer’s Disease
From Setbacks to Stepping Stones
Innovation is a Collaborative Mission
Rx Minute: Statins Value to Society & Risk Factors Linked to Alzheimer’s
Rx Minute: Alzheimer’s Burden Will Balloon if New Treatments Are Not Found
1 of 3next ›
More On PhRMA — powered by PhRMApedia
RESOURCES
Supply Chain Security
Securing the Supply Chain
MOST READ
Press Room
PhRMApedia Press Room
RECOMMENDED
Medicines in Development for Older Americans
Medicines in Development for Older Americans
– See more at: http://www.phrma.org/research/medicines-development-alzheimers-disease#sthash.4Hkh2kIa.dpuf
Source: Pharmaceutical Research and Manufacturers of America WEBSITE http://www.phrma.org/research/medicines-development-alzheimer‘s-disease